When mpox cases surged in 2022, health departments faced the urgent task of getting treatment to people who needed it. A new report focuses on how Los Angeles County handled the distribution of tecovirimat, the antiviral drug used to treat mpox.
The report describes the distribution effort itself, but it doesn't include any results about whether the treatment helped people recover faster, prevented severe illness, or caused any side effects. We don't know how many people received the drug or what their outcomes were.
This means we can't draw conclusions about tecovirimat's effectiveness from this information alone. The report offers a snapshot of one county's public health response during a crisis, which is valuable for planning, but it leaves the medical questions about the treatment unanswered.
